Market Overview

Physician Views Off-Label Use A 'Double-Edged Sword' For TG Therapeutics

Share:
Physician Views Off-Label Use A 'Double-Edged Sword' For TG Therapeutics
Related
Don't Let Offerings Blindside Your Thesis
25 Stocks Moving In Tuesday's Pre-Market Session

Reni Benjamin of Raymond James maintains a Strong Buy rating on TG Therapeutics Inc (NASDAQ: TGTX) after hosting an investor meeting with Charles Farber, a notable physician at the Summit Medical Group.

Benjamin noted Farber's practice treats approximately 80 patients per week who suffer from chronic lymphocytic leukemia, of which up to 12 are being treated with TG Therapeutics' ibrutinib.

The doctor also said that among new patients recently diagnosed with CLL, one-third need treatment right away, one-third will likely be treated anywhere from one to 10 years down the road and the remaining one-third don't receive any treatment.

Among the patients who require therapy, Farber does not think there is a mandatory guideline in terms of which regimen needs to be prescribed since every patient is different.

Double-Edged Sword

Farber told the analyst he prefers not to prescribe a patient with an off-label therapy, as this creates a risk of not being reimbursed for an oncology drug.

Benjamin believes Farber's comments are likely shared across the community setting and should be viewed as a "double-edged sword." On one hand, physicians wouldn't "substitute rituximab or Gazyva for TG-1101 if the TG-1101/ibrutinib combination were to be approved in relapsed/refractory high-risk CLL," which is a clear positive for TG Therapeutics. On the other hand, "If the combination is approved in
the r/r setting, it is unlikely to be used in the front-line setting unless the company is able to secure a very broad label" — something which is unlikely.

The Winning Combination

Farber indicated that if TG-1101 plus ibrutinib is approved for high-risk CLL patients he would "certainly" give the combination instead of ibrutinib monotherapy given a superior greater overall response rate based on the Phase III GENUINE results.

Finally, Farber argued for his preferences of the combo, especially if it gets a broader label to include all patients, although the analyst believes this is "not likely."

Related Links:

Don't Let Offerings Blindside Your Thesis

TG Therapeutics Pulling Off The Band-Aid To Keep GENUINE Cancer Study On Track

Latest Ratings for TGTX

DateFirmActionFromTo
Mar 2017H.C. WainwrightReiteratesBuy
Feb 2017Aegis CapitalInitiates Coverage OnBuy
Oct 2016Brean CapitalAssumesBuy

View More Analyst Ratings for TGTX
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech Long Ideas Health Care Reiteration Analyst Ratings Trading Ideas General Best of Benzinga

 

Related Articles (TGTX)

View Comments and Join the Discussion!